Simple Summary The tumor microenvironment, especially tumor-associated fibroblasts (TAFs), has been extensively studied in cancer, but not as much in pituitary adenoma (PA). Studies of TAFs will provide a better understanding of the mechanisms by which PA exhibits aggressive behavior. Our study proved that TAFs promote PA progression through exosomal circDennd1b. circDennd1b, as a ceRNA, upregulated the expression of the target gene ONECUT2 by sponging miR-145-5p, thereby transcriptionally regulating FGFR3 and activating the downstream MAPK pathway and finally promoting the PA progression. Moreover, the suppression of ONECUT2 and TAFs can improve the efficacy of clinical drugs for PA. TAF participated in the progression of various cancers, including PA via the release of soluble factors. Exosomes belonged to extracellular vesicles, which were revealed as a crucial participator in intercellular communication. However, the expression pattern and effect of TAF-derived exosomes remained largely unknown in PA. In the present study, we performed in silico analysis based on public RNA-seq datasets to generate the circRNA/miRNA regulatory network. The qRT-PCR, Western blotting, RNA pull-down, and luciferase assay were performed to investigate the effect of TAF-derived exosomes. TAF-derived exosomal circDennd1b was significantly upregulated in PA and promoted the proliferation, migration, and invasion of PA cells via sponging miR-145-5p in PA cells. In addition, miR-145-5p directly regulated One Cut homeobox 2 (ONECUT2/OC2) expression and inhibited the promoting effect of ONECUT2 on PA. We further demonstrated that ONECUT2 transcriptionally increased fibroblast growth factor receptor 3 (FGFR3) expression, which further activates the mitogen-activated protein kinases (MAPK) pathway, thus promoting PA progression. Moreover, the suppression of TAFs by ABT-263 and ONECUT2 by CSRM617 inhibited the growth of PA. In conclusion, our study illustrated that TAF-derived exosomal circDennd1b affected PA progression via regulating ONECUT2 expression, which provides a potential therapeutic strategy against aggressive PA.
